Joanna Pepke-Zaba, PhD, FRCP, graduated from Warsaw University School of Medicine in Poland before undertaking a fellowship in respiratory physiology at Royal Papworth and Addenbrooke’s Hospitals, University of Cambridge, which resulted in a PhD. She is the lead physician and Director of the National Pulmonary Vascular Diseases Unit at Royal Papworth Hospital. She is member of Pulmonary Hypertension Clinical Reference Group and  previously chaired the National Pulmonary Hypertension (PH) Centres Committee for the UK and Ireland.  Her main research has concentrated on the translational programmes  in the field of pulmonary hypertension with specific interest into Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.

Has published over 100 papers in the field of PH and serves on various educational and scientific international committees. She is committed to training in respiratory medicine and was reappointed as Recognised Teacher by the Clinical School of the University of Cambridge. She has been Honorary Senior Visiting Fellow of the University of Cambridge School of Clinical Medicine since 2011.
 

Research Interests

Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension.

Education and Training

1977   Lek med., equivalent of MBBS
1984  -  Specialist in Internal Medicine, Polish equivalent of CCST
1995  - PhD degree with distinction, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; based on the research carried out at Papworth and Addenbrooke’s Hospitals, Cambridge, U.K.
2002 -  Specialist Register:  General (internal) Medicine and Respiratory Medicine

Current membership(s) of professional, national and regional bodies and university posts

2008 -  Fellow of Royal College of Physicians
2011 Honorary Senior Visiting Fellow of the University of Cambridge School of Clinical Medicine
GMC, BTS, ERS

Recent and Important Publications

Right Ventricular Dysfunction in Chronic Thromboembolic Obstruction of the Pulmonary Artery. McCabe C, White PA, Hoole SP, Axell RG, Priest AN, Gopalan D, Taboada D, Mackenzie Ross RV, Morrell NW, Shapiro LM, Pepke-Zaba J. J Appl Physiol . 2014;116(4):355-63

Pulmonary arterial hypertension: epidemiology and registries. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. J Am Coll Cardiol. 2013;62(25 Suppl):D51-9

Inefficient exercise gas exchange identifies pulmonary hypertension in chronic thromboembolic obstruction following pulmonary embolism. McCabe C, Deboeck G, Harvey I, Ross RM, Gopalan D, Screaton N, Pepke-Zaba J. Thromb Res. 2013 132:659-65

Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. Mackenzie Ross RV, Toshner MR, Soon E, Naeije R, Pepke-Zaba J. Am J Physiol Heart Circ Physiol. 2013 ;305(2):H259-64

Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambro� D, Blanco I, Torbicki A, Mellemkjaer S, Yaici A, Delcroix M. Thromb Haemost. 2013;110(1):83-91

Patient-reported outcomes assessed by CAMPHOR questionnaire predict clinical deterioration in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension" McCabe C, Bennett  M, Doughty  N, Mackenzie Ross R,  Sharples  L, Pepke-Zaba J. CHEST 2013.. 144(2):522-30

Chronic Thromboembolic Pulmonary Hypertension: Role of medical therapy.  Pepke-Zaba J, Jansa P,  Kim NH, Naejie R, Simonneau G.  Eur Respir J. 2013;41(4):985-90

Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. Pepke-Zaba J, Hoeper MM, Humbert M. Eur Respir J. 2013;41:8-9

Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. in CTEPH.  Toshner M,  Suntharalingam J, Fesler P,  Soon  E, Sheares K,  Jenkins D,  White P,  Morrell NW,  Naeije R,  Pepke-Zaba J. Eur Respir J 2012;40:612-7 

Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results from an International Prospective Registry. Pepke-Zaba J; Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C,  D'Armini A, Morsolini M, Snijder R,  Bresser P, Torbicki A, Kristensen B, LewczukJ, Simkova I,  Barberà J, de Perrot M, Hoeper M,  Gaine S, Speich R, Gomez-Sanchez M, Kovacs G,  Monem Hamid A, Jaïs X, Simonneau G. Circulation  2011;124(18):1973-81

Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Soon E ,  Treacy C,  Toshner M,  MacKenzie Ross R, Manglam V,  Busbridge M,  Sinclair-McGarvie M,  Arnold J,  Sheares K,  Morrell N, Pepke-Zaba J. Thorax 2011;66:326-32.

Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients. Soon E, Toshner M, Mela M, Grace A, Sheares K, Morrell N, Pepke-Zaba J. J Am Coll Cardiol. 2011;57(8):997-8